Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Flaherty

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Future Oncology (London, England)|May 26, 2025
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.
Oncotarget|March 2, 2018
Distinct histone modifications denote early stress-induced drug tolerance in cancerAbdullah Al Emran, Diego M Marzese, Dinoop Ravindran Menon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2020
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant MelanomaCharles Marusak, Varsha Thakur, Yuan Li, et al.
Neuro-Oncology Advances|May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
Science Signaling|January 31, 2013
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cellsDaniela Beck, Heike Niessner, Keiran S M Smalley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic MelanomaReinhard Dummer, Shibing Deng, Tao Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
It is time to include patients with brain tumors in phase I trials in oncologyPatrick Y Wen, David Schiff, Timothy F Cloughesy, et al.
JCO Oncology Practice|August 29, 2023
Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data QualityJoseph M Unger, Hillary Stires, Laura A Levit, et al.
Molecular Cancer Research : MCR|June 24, 2020
SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma GrowthIkrame Lazar, Bertrand Fabre, Yongmei Feng, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Future Oncology (London, England)|May 26, 2025
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.
Oncotarget|March 2, 2018
Distinct histone modifications denote early stress-induced drug tolerance in cancerAbdullah Al Emran, Diego M Marzese, Dinoop Ravindran Menon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2020
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant MelanomaCharles Marusak, Varsha Thakur, Yuan Li, et al.
Neuro-Oncology Advances|May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
Science Signaling|January 31, 2013
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cellsDaniela Beck, Heike Niessner, Keiran S M Smalley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic MelanomaReinhard Dummer, Shibing Deng, Tao Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
It is time to include patients with brain tumors in phase I trials in oncologyPatrick Y Wen, David Schiff, Timothy F Cloughesy, et al.
JCO Oncology Practice|August 29, 2023
Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data QualityJoseph M Unger, Hillary Stires, Laura A Levit, et al.
Molecular Cancer Research : MCR|June 24, 2020
SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma GrowthIkrame Lazar, Bertrand Fabre, Yongmei Feng, et al.
Pageof 7